Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votes
GovInfo API
Floor speeches, reports, bill text
Federal Election Commission (FEC)
Campaign finance
VoteView (UCLA)
Ideology scores (DW-NOMINATE)
GovTrack.us
Misconduct data (CC0)
U.S. Census Bureau
District demographics
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

Press ReleaseUrgent2026-05-05

Rep. Jimmy Gomez Joins 250+ Democrats Urging Supreme Court to Protect Access to Mifepristone

Jimmy Gomez
Jimmy Gomez
DCA-34 · Representative
Share:
Healthcare

Context

This press release from Representative Jimmy Gomez (D-CA) was published on 2026-05-05 and titled "Rep. Jimmy Gomez Joins 250+ Democrats Urging Supreme Court to Protect Access to Mifepristone". It focuses on healthcare.

Full Text

Rep. Jimmy Gomez Joins 250+ Democrats Urging Supreme Court to Protect Access to Mifepristone

WASHINGTON, D.C. — Congressman Jimmy Gomez joined more than 250 House and Senate Democrats in filing an amicus brief urging the Supreme Court to overturn a Fifth Circuit decision that threatens access to mifepristone, undermines women’s health care, and weakens the FDA’s long-established scientific approval process. The brief follows emergency appeals from mifepristone manufacturers and a temporary stay issued by the Supreme Court while the case moves forward. In the filing, lawmakers argued that mifepristone has been repeatedly proven safe and effective through the FDA’s rigorous approval and review process. They warned that allowing courts to override science-based decisions made by medical experts would set a dangerous precedent and further restrict access to reproductive health care across the country. “For more than 25 years, the FDA has consistently affirmed that mifepristone is safe and effective, and millions of patients have used it safely,” the lawmakers wrote in the brief. “Allowing courts to overrule evidence-based medical decisions threatens both access to care and the integrity of the FDA’s approval process.” The lawmakers also emphasized that reinstating burdensome in-person dispensing requirements would disproportionately harm patients in communities where reproductive health care providers are already difficult to access. The amicus brief was signed by all 47 Senate Democrats and 212 House Democrats. The full amicus brief can be viewed HERE .
View original source →